SEARCH:   Advanced

Blood, 15 February 2007, Vol. 109, No. 4, pp. 1765-1772. Prepublished online as a Blood First Edition Paper on October 17, 2006; DOI 10.1182/blood-2006-05-022335. This Article Full Text (PDF) All Versions of this Article: blood-2006-05-022335v1 109/4/1765    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Baker, K. S. Articles by Bhatia, S. Search for Related Content PubMed PubMed Citation Articles by Baker, K. S. Articles by Bhatia, S. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 11, 2006 Accepted September 24, 2006 Diabetes, hypertension and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplant survivor study K. Scott Baker*, Kirsten K Ness, Julia Steinberger, Andrea Carter, Liton Francisco, Linda J Burns, Charles Sklar, Stephen Forman, Daniel J. Weisdorf, James G Gurney, and Smita Bhatia Depts of Pediatrics & Medicine, University of Minnesota, Minneapolis, MN Division of Populations Sciences, City of Hope National Medical Center, Duarte, CA Dept of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY Division of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA Dept of Pediatrics, University of Michigan, Ann Arbor, MI * Corresponding author; email: baker084{at}umn.edu. We ascertained the prevalence of self-reported late occurrence of diabetes, hypertension, and cardiovascular (CV) disease in 1089 hematopoietic cell transplant (HCT) survivors who underwent HCT between 1974-1998, survived 2 years and were not currently taking immunosuppressant agents, and compared them to 383 sibling controls. All subjects completed a 255-item health questionnaire. The mean age at survey completion was 39.8 yrs for survivors and 38.6 yrs for siblings, mean follow-up was 8.3 years. Adjusting for age, gender, race, and body mass index (BMI), survivors of allogeneic HCT were 3.65 times (95% CI: 1.82-7.32) more likely to report diabetes than siblings and 2.06 times (95% CI 1.39-3.04) more likely to report hypertension compared to siblings, but did not report other CV outcomes with any greater frequency. Recipients of autologous HCT were no more likely than siblings to report any of the outcomes studied. Allogeneic HCT survivors were also more likely to develop hypertension (OR= 2.31, 95% CI: 1.45-3.04) than autologous recipients. TBI exposure was associated with an increased risk of diabetes (OR=3.42, 95% CI: 1.55-7.52). Thus, HCT survivors have a higher age- and BMI-adjusted risk of diabetes and hypertension, potentially leading to a higher than expected risk of CV events with age. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020